← Back to Search

Vasopressor

Midodrine for Sepsis

Phase 2 & 3
Recruiting
Led By Amos Lal, MBBS
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 28 days
Awards & highlights
No Placebo-Only Group

Summary

This trial aims to see if giving Midodrine early can help people with sepsis need less medication to maintain their blood pressure. If successful, this could lead to shorter hospital stays, less time

Who is the study for?
This trial is for individuals with sepsis and low blood pressure who may benefit from an alternative to intravenous medications. Specific eligibility criteria are not provided, but typically participants would need to meet certain health conditions.
What is being tested?
The study tests if Midodrine, taken early on, can help maintain higher blood pressure in septic shock patients without needing IV meds. It's compared against a placebo to see if it reduces the need for vasopressors.
What are the potential side effects?
While specific side effects of Midodrine in this context aren't listed, generally it can cause tingling scalp sensations, chills or goosebumps, urinary urgency or problems with urination due to its action on blood vessels.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~28 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 28 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Time alive and without vasopressor support
Secondary study objectives
Central venous access duration
Hospital Length of Stay
ICU Length of Stay
+2 more

Side effects data

From 2012 Phase 4 trial • 29 Patients • NCT00108355
8%
GI Bleeding
8%
Hepatic encephalopathy
8%
Scrotal edema
100%
80%
60%
40%
20%
0%
Study treatment Arm
Albumin (Control Group)
Vasoconstrictor (Treatment Group)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Standard of Care with Midodrine GroupExperimental Treatment1 Intervention
Subjects will receive standard of care for sepsis and three doses of midodrine every 8 hours.
Group II: Standard of Care GroupActive Control1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Midodrine
2008
Completed Phase 4
~1160

Find a Location

Who is running the clinical trial?

Mayo ClinicLead Sponsor
3,362 Previous Clinical Trials
3,065,691 Total Patients Enrolled
Amos Lal, MBBSPrincipal InvestigatorMayo Clinic
~180 spots leftby May 2029
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top